New Cholesterol Drug for Kidney Patients
Data shows enlicitide helps adults with reduced kidney function reach lower LDL cholesterol levels.
Updated on Oct. 24, 2026 in Heart Disease
Live Poll
Should medical studies be required to include specific data for patients with pre-existing kidney disease?
New trial data shows the medication enlicitide effectively lowers LDL cholesterol in patients with reduced kidney function. This may provide an important new treatment option for those at elevated cardiovascular risk.
Why it matters
People with reduced kidney function are at a higher risk for cardiovascular disease but often struggle to reach target cholesterol levels with existing treatments. This data suggests enlicitide could help bridge that gap for patients who need more intensive lipid management.
A pooled analysis of 3,212 participants found that enlicitide significantly reduced LDL-C in patients with varying levels of kidney function compared to placebo. It remains unclear if this reduction directly translates to a decrease in cardiovascular mortality or morbidity.
The players
FDA
The federal agency responsible for evaluating the safety and efficacy of new drugs before they are approved for public use.
The details
Enlicitide works to lower LDL cholesterol levels, and its efficacy appears consistent even in patients with lower estimated glomerular filtration rates (eGFR). Because food intake can significantly reduce the drug's absorption, patients must take the 20 mg tablet on an empty stomach in the morning. It is essential to wait at least 30 minutes after dosing before eating or drinking anything other than water, black coffee, or plain tea to ensure the medication maintains its full steady-state exposure.
Timeline
July 2026: FDA approved enlicitide 20 mg once daily.
October 2026: Data was presented at Kidney Week 2026 in Denver.
Week 24: LDL-C reductions were measured in clinical study participants.
Week 52: Adverse events and long-term lipid changes were assessed.
Health Landscape
This development addresses a critical challenge in managing cardiovascular risk for patients with impaired kidney function, who are often excluded from or respond differently to standard lipid-lowering therapies. Researchers are currently tracking the CORALreef Outcomes trial to determine if this cholesterol reduction translates into tangible improvements in patient survival.
If you have reduced kidney function and are managing high cholesterol, this drug represents a new option that is worth discussing with your doctor. Always follow the strict timing instructions for taking the medication, as consuming food too soon can interfere with how your body absorbs the drug.
The takeaway
Enlicitide shows promise for lowering cholesterol in patients with kidney-related cardiovascular risk. When starting any new medication, ensure you understand the specific timing requirements for food and drink intake to guarantee the treatment is as effective as possible.
Further reading
For more on managing heart health, visit Heart Disease.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Should medical studies be required to include specific data for patients with pre-existing kidney disease?
